Peter M. Allen

N8 Medical, Inc. is an American clinical stage biotechnology company that develops anti-fouling medical devices to reduce infections, complications, and mortality. The private company is based in an undisclosed location and has a platform technology called Cerashield™, which is based on ceragenins, a novel compound invented by Professor Paul B. Savage. The technology has been featured in over 90 peer-reviewed journal articles. Marc H. Rohman has been the CEO of the company since 2019.

N8 Medical, Inc. is an American clinical stage biotechnology company that develops anti-fouling medical devices to reduce infections, complications, and mortality. The private company is based in an undisclosed location and has a platform technology called Cerashield™, which is based on ceragenins, a novel compound invented by Professor Paul B. Savage. The technology has been featured in over 90 peer-reviewed journal articles. Marc H. Rohman has been the CEO of the company since 2019.

N8 Medical, Inc. is an American clinical stage biotechnology company that develops anti-fouling medical devices to reduce infections, complications, and mortality. The private company is based in an undisclosed location and has a platform technology called Cerashield™, which is based on ceragenins, a novel compound invented by Professor Paul B. Savage. The technology has been featured in over 90 peer-reviewed journal articles. Marc H. Rohman has been the CEO of the company since 2019.

N8 Medical, Inc. is an American clinical stage biotechnology company that develops anti-fouling medical devices to reduce infections, complications, and mortality. The private company is based in an undisclosed location and has a platform technology called Cerashield™, which is based on ceragenins, a novel compound invented by Professor Paul B. Savage. The technology has been featured in over 90 peer-reviewed journal articles. Marc H. Rohman has been the CEO of the company since 2019.